Survival Effect Difference of Whole-Brain Radiation Therapy and TKIs in Patients with Brain Metastases from Non-Small Cell Lung Cancer Stratified by EGFR Mutation Status
Z. Li,J. Zhang,D. Shen,H. Han,D. Kong,J. Kong,A. Zhang
DOI: https://doi.org/10.1016/j.ijrobp.2018.07.941
2017-01-01
Abstract:To evaluate overall (OS) and intracranial progression-free survival (PFS) effects of whole-brain radiotherapy (WBRT) and other factors in lung cancer (LC) patients with brain metastases (BM) We performed a retrospective analysis of 828 patients diagnosed with BM from LC in 2013-2015. Characteristics of disease and treatment history were collected with their survival till December 1 2016. RT modalities were classified: none, <30, 30-39 and ≥40 Gy of WBRT; none, <50, 50-59 and ≥60 Gy of largest BM site dose; gamma-knife/SRS use or not. Cox proportional hazard models evaluated the effects of WBRT regimen and other factors on OS and PFS. Beside RT modalities, final model variables included sex, BM age, KPS, pathology (SCLC/NSCLC/No-Record), number of brain lesion (1,2-3,≥4), BM resection status, BM chemotherapy, target drug use, meningeal or brain stem involvements, extracranial metastases, CVD comorbidity, primary LC tumor resection, and LC days at BM after extensive screening univariate analyses on others. p<0.05 as ns. BM age mean (range) was 59 (22 - 90) and male 506 (61%). By the WBRT regiment order above, number (median days of OS vs. PFS.) patients were 451(205 vs. 177 days), 43(140 vs. 112), 137(353 vs. 337) and 197(353 vs. 332) with both K-M log-rank tests p<0.001. Compared with none, other WBRT regimen's univariate hazard ratios (HRs) of OS were 1.677 (p=0.003), 0.678 (p<0.001) and 0.603(p<0.001) and their HRs of PFS were 1.850 (p<0.001), 0.627 (p<0.001) and 0.611(p<0.001). On multivariate analyses, their HRs of OS were 1.292 (ns), 0.638(p=0.003), 0.559 (p<0.001) and their HRs of PFS were 1.479 (0.033), 0.562 (p<0.001) and 0.570 (p<0.001). Prognostic factors with both extended survivals were female, high KPS, single BM site, extracranial metastases absence, chemotherapy, target drug use, and LC < 30 days at BM diagnosis. Worse PFS for patients with WBRT <30 Gy was likely due to selection bias. WBRT associates independently with improved OS and PFS for BM patients from LC. WBRT ≥40 Gy provides no more survival benefit.